MicroRNA-106b-5p promotes hepatocellular carcinoma development via modulating FOG2
Open accessAbstract
Background: A recent study has revealed that miR-106b-5p might promote hepatocellular carcinoma (HCC) stemness maintenance and metastasis by targeting PTEN via PI3K/Akt pathway based on HCC cell lines and animal models. Its clinical relevance remains unknown. Purpose: Herein, we aimed to evaluate associations of miR-106b-5p dysregulation with various clinicopathological features of HCC patients and investigate its functions during HCC progression. Patients and methods: At first, miR-106b-5p expression in 130 pairs of HCC and adjacent normal liver tissues was detected by quantitative PCR. Chi-square test was then performed to determine clinical significance. Further investigations on its functions were performed by miRNA target prediction and validation, as well as cellular experiments. Results: miR-106b-5p levels in HCC tissues were significantly higher than those in the adjacent normal liver tissues ( P <0.001). High miR-106b-5p expression was significantly associated with advanced tumor stage ( P =0.02) and high tumor grade ( P =0.03). In addition, Friend of GATA 2 (FOG2) was identified as a direct target of miR-106b-5p in HCC cells. Moreover, the clinical relevance to HCC progression of the combined high miR-106b-5p and low FOG2 expression was more significant than high miR-106b-5p alone. Functionally, enforced expression of miR-106b-5p reduced FOG2 expression and promoted the proliferation and invasion of HCC cells. Furthermore, co-transfection of FOG2 restored the oncogenic roles of miR-106b-5p over-expression. Conclusion: Our data offer the convincing evidence that miR-106b-5p upregulation may promote the aggressive progression of HCC. miR-106b-5p overexpression may promote HCC cell proliferation and invasion by suppressing FOG2, implying its potentials as a promising therapeutic target for HCC patients. Keywords: hepatocellular carcinoma, microRNA-106b-5p, friend of GATA 2, tumor progression, prognosis
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miR-106b-5p is an oncogenic miRNA that appears to be upregulated in hepatic cancer, cervical cancer, gliomas, and gastric cancer.
“miR-106b-5p is an oncogenic miRNA that appears to be upregulated in different cancers, such as hepatic cancer,232 cervical cancer,233 gliomas,234 and gastric cancer.235”
From Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential (2023) · cites this paper as [232]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: MicroRNA‐106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells
Ying, X., Wang, K., Gao, W., Zhang, C., Fuhui, H., Shu-xin, W., & Binquan, W. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.069 · Cited by 45 · see citing works
RetractedMolecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,948 · see citing works
Circular RNA and its mechanisms in disease: From the bench to the clinic
Han, B., Chao, J., & Yao, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.010 · Cited by 784 · see citing works
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561 · see citing works
Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer
Liu, H., Lei, C., He, Q., Zou, P., Xiao, D., & Tao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0765-5 · Cited by 336 · see citing works
Self-citationCell Cycle Regulation of Stem Cells by MicroRNAs
Mens, M. M. J., & Ghanbari, M. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9808-y · Cited by 220 · see citing works
Cancer Hallmarks and MicroRNAs: The Therapeutic Connection
Roosbroeck, K. V., & Călin, G. A. (2017) · Advances in cancer research · doi:10.1016/bs.acr.2017.06.002 · Cited by 164 · see citing works
Zhang, Y., Guo, X., Xiong, L., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-253 · Cited by 96 · see citing works
MicroRNA Roles in the Nuclear Factor Kappa B Signaling Pathway in Cancer
Wu, J., Ding, J., Yang, J., Guo, X., & Zheng, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00546 · Cited by 94 · see citing works
MicroRNA-106b-5p boosts glioma tumorigensis by targeting multiple tumor suppressor genes
Liu, F., Gong, J., Huang, W., Wang, Z., Wang, M., Yang, J., Wu, C., Wu, Z., & Han, B. (2014) · Oncogene · doi:10.1038/onc.2013.428 · Cited by 86 · see citing works
Park, J. T., Kato, M. V., Yuan, H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.453043 · Cited by 83 · see citing works
Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist
Quaglia, A. (2018) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s159808 · Cited by 69 · see citing works
Xiao, Y., Wang, J., Chen, Y., Zhou, K., Wen, J., Wang, Y., Zhou, Y., Pan, W., & Cai, W. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.003 · Cited by 68 · see citing works
miR-200s Contribute to Interleukin-6 (IL-6)-induced Insulin Resistance in Hepatocytes
Dou, L., Zhao, T., Wang, L., Huang, X., Jiao, J., Gao, D., Zhang, H., Shen, T., Man, Y., Wang, S., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.423145 · Cited by 67 · see citing works
Wei, K., Pan, C., Yao, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485650 · Cited by 61 · see citing works
Shi, D.-M., Bian, X., Qin, C., & Wu, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152611 · Cited by 60 · see citing works
MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages
Curtale, G. (2018) · Cells · doi:10.3390/cells7020012 · Cited by 57 · see citing works
Lu, J. K., Wei, J., Feng, Z., Chen, Z., Wang, Y., Huang, Y., Fang, Y., Liang, Y., Cen, J., Pan, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15591 · Cited by 51 · see citing works
Yu, S., Qin, X., Chen, T., Zhou, L., Xu, X., & Feng, J. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000524 · Cited by 45 · see citing works
Mei, S., Xin, J., Liu, Y., Zhang, Y., Liang, X., Su, X., Yan, H., Huang, Y., & Yang, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135867 · Cited by 44 · see citing works
Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens
Choi, W., Ramachandran, R., & Kakar, S. (2017) · Human Pathology · doi:10.1016/j.humpath.2016.12.025 · Cited by 41 · see citing works
Zhang, Y., Guo, X., Li, Z., et al. (2015) · RNA Biology · doi:10.1080/15476286.2015.1022702 · Cited by 34 · see citing works
Micro RNA ‐200 promotes lung cancer cell growth through FOG2 ‐independent AKT activation
Guo, L., Wang, J., Yang, P., et al. (2015) · IUBMB Life · doi:10.1002/iub.1412 · Cited by 29 · see citing works
Ma, T., Cai, X., Wang, Z., Huang, L., Wang, C., Jiang, S., Hua, Y., & Liu, Q. (2017) · BioMed Research International · doi:10.1155/2017/2670658 · Cited by 28 · see citing works
The role of miR-200a in mammalian epithelial cell transformation
Becker, L. E., Takwi, A. A., Lu, Z., & Li, Y. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu202 · Cited by 27 · see citing works
miR106b regulates retinoblastoma Y79 cells through Runx3
Yang, G., Fu, Y., Zhang, L., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5931 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246 · see citing works
“…cardiovascular diseases, metabolic diseases, immune-mediated disorders, and neurological disorders, etc. 230,231 For example, miR-106b-5p is an oncogenic miRNA that appears to be upregulated in different cancers, such as hepatic cancer, 232 cervical cancer, 233 gliomas, 234 and gastric cancer.”
Background
- Authors
- Yu, L.-X., Zhang, B.-L., Yang, M.-Y., Liu, H., Xiao, C.-H., Zhang, S.-G., & Liu, R.
- Affiliations
- 302 Military Hospital of China (CN)
- Chinese PLA General Hospital (CN)
- Corresponding author
- Liu, Rong
- ORCID
- Liu, Rong
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-07
- Volume
- Volume 12
- Pages
- 5639-5647
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6642636
- OpenAlex
- W2960552578
- Cited by
- 20
- References
- 26
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- miR-106b-5p, FOG2, hepatocellular carcinoma, microRNA, tumor progression, cell proliferation, tumor invasion, prognostic factors, therapeutic target, tumor stage and grade
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
